[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) filed a Form 144 disclosing a proposed sale of 169,206 common shares, with an aggregate market value of $1,568,539.00, to occur approximately on 08/13/2025 on NASDAQ through Charles Schwab Corp. The filing shows the shares were acquired by RSU vesting in March 2023 in three tranches: 87,719 on 03/12/2023, 36,197 on 03/01/2023 and 45,290 on 03/03/2023. The notice also records a sale during the past three months: Anastasios Konidaris sold 111,635 shares on 08/13/2025 for gross proceeds of $1,021,157.97. The signee represents there is no undisclosed material adverse information.

Positive

• Clear disclosure of planned Rule 144 sale showing quantity (169,206 shares) and aggregate market value ($1,568,539.00).
• Acquisition details provided (RSU vesting dates and tranche amounts), improving transparency about the origin of the shares.
• Broker identified (Charles Schwab Corp.), indicating execution through a regulated brokerage channel.

Negative

• Insider executed a recent sale of 111,635 shares on 08/13/2025 for gross proceeds of $1,021,157.97, increasing available supply of insider-held shares.
• Form does not disclose whether sales are governed by a dated 10b5-1 plan (no plan adoption date provided), leaving the trading authorization context unspecified.

Insights

Financial Analyst

TL;DR: Insider Form 144 discloses RSU-derived sale of 169,206 shares; recent sale of 111,635 generated $1.02M—routine disclosure.

The filing documents a planned sale of 169,206 common shares valued at $1,568,539.00 and executed via Charles Schwab on NASDAQ on 08/13/2025. Acquisition details show the shares stem from RSU vesting in March 2023 (three tranches totaling 169,206). A prior transaction by Anastasios Konidaris on 08/13/2025 sold 111,635 shares for $1,021,157.97. These are standard insider-disclosure items showing monetization of equity awards; the filing includes the required representation that no material nonpublic information is known to the seller.

Corporate Governance Expert

TL;DR: Filing shows executive sales from RSU vesting and confirms no undisclosed material information per signee—standard compliance step.

The Form 144 lists the broker (Charles Schwab Corp.) and provides transaction-level acquisition dates and amounts for RSU vesting in March 2023. The presence of a recent reported sale (111,635 shares, $1,021,157.97) and the seller's attestation about material information are consistent with routine Rule 144 compliance. The notice references the potential existence of a trading plan or instructions under Rule 10b5-1 without providing plan dates, so the filing focuses on disclosure and procedural conformity rather than new governance events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	169206	1568539.00	314079309	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/12/2023	RSU Vesting	Issuer			87719	03/12/2023	N/A
Common	03/01/2023	RSU Vesting	Issuer			36197	03/01/2023	N/A
Common	03/03/2023	RSU Vesting	Issuer			45290	03/03/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Anastasios Konidaris 400 CROSSING BOULEVARD, 3RD FLOOR, BRIDGEWATER NJ 08807	Common	08/13/2025	111635	1021157.97

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AMRX Form 144 filed on this document disclose?

The filing discloses a proposed sale of 169,206 common shares of Amneal (AMRX) valued at $1,568,539.00, to be sold on or about 08/13/2025 on NASDAQ through Charles Schwab Corp.

Where did the shares come from according to the Form 144?

The shares were acquired via RSU vesting in March 2023 in three tranches: 87,719 on 03/12/2023; 36,197 on 03/01/2023; and 45,290 on 03/03/2023.

Did the filer report any recent sales in the past three months?

Yes. Anastasios Konidaris sold 111,635 common shares on 08/13/2025 for gross proceeds of $1,021,157.97.

Which broker and exchange are listed for the proposed sale?

Broker: Charles Schwab Corp., 3000 Schwab Way Westlake TX 76262. Exchange: NASDAQ.

Does the Form 144 include the seller's attestation about material information?

Yes. The signer represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.